<?xml version="1.0" encoding="UTF-8"?>
<p>As a guanine analog, favipiravir inhibits the key viral enzyme RNA-dependent RNA polymerase [
 <xref rid="B30-pharmaceuticals-13-00096" ref-type="bibr">30</xref>]. Favipiravir has been approved for the treatment of influenza viruses type A and B in a few Asian countries. The use of favipiravir in mild cases of COVID-19 was reported by a single study to be associated with a better viral clearance and more frequent radiological improvement compared with lopinavir/ritonavir combined therapy. The analysis was an open-label and non-randomized. Surprisingly, the manuscript was temporarily removed. However, favipiravir has been included in several trials in combination with other antiviral drugs (including lopinavir/ritonavir); see 
 <xref rid="pharmaceuticals-13-00096-t001" ref-type="table">Table 1</xref>. 
</p>
